Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 4
2005 6
2006 2
2007 1
2008 3
2009 4
2010 2
2011 5
2012 7
2013 3
2014 2
2015 8
2016 10
2017 4
2018 3
2019 8
2020 9
2021 8
2022 9
2023 6
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Results by year

Filters applied: . Clear all
Page 1
Epidemiology of COPD.
Raherison C, Girodet PO. Raherison C, et al. Among authors: girodet po. Eur Respir Rev. 2009 Dec;18(114):213-21. doi: 10.1183/09059180.00003609. Eur Respir Rev. 2009. PMID: 20956146 Free article. Review.
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Patel N, Yancopoulos GD, Akinlade B, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB; NOTUS Study Investigators. Bhatt SP, et al. N Engl J Med. 2024 Jun 27;390(24):2274-2283. doi: 10.1056/NEJMoa2401304. Epub 2024 May 20. N Engl J Med. 2024. PMID: 38767614 Clinical Trial.
Reply.
Vandenborght LE, Enaud R, Urien C, Coron N, Girodet PO, Ferreira S, Berger P, Delhaes L. Vandenborght LE, et al. Among authors: girodet po. J Allergy Clin Immunol. 2021 Feb;147(2):779-780. doi: 10.1016/j.jaci.2020.10.021. Epub 2020 Dec 1. J Allergy Clin Immunol. 2021. PMID: 33276993 No abstract available.
Benralizumab for the Prevention of COPD Exacerbations.
Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators. Criner GJ, et al. N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20. N Engl J Med. 2019. PMID: 31112385 Clinical Trial.
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.
Jackson DJ, Heaney LG, Humbert M, Kent BD, Shavit A, Hiljemark L, Olinger L, Cohen D, Menzies-Gow A, Korn S; SHAMAL Investigators. Jackson DJ, et al. Lancet. 2024 Jan 20;403(10423):271-281. doi: 10.1016/S0140-6736(23)02284-5. Epub 2023 Dec 7. Lancet. 2024. PMID: 38071986 Free article. Clinical Trial.
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G; DESTINATION study investigators. Menzies-Gow A, et al. Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23. Lancet Respir Med. 2023. PMID: 36702146 Clinical Trial.
Strategies for Identifying Biomarkers in Severe Asthma.
Girodet PO. Girodet PO. Am J Respir Crit Care Med. 2024 Aug 1;210(3):251-252. doi: 10.1164/rccm.202404-0707ED. Am J Respir Crit Care Med. 2024. PMID: 38701409 Free PMC article. No abstract available.
[Pathophysiology of asthma].
Ozier A, Bara I, Girodet PO, Marthan R, Berger P. Ozier A, et al. Among authors: girodet po. Rev Prat. 2011 Mar;61(3):339-45. Rev Prat. 2011. PMID: 21563408 French.
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG; ANDHI study investigators. Harrison TW, et al. Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22. Lancet Respir Med. 2021. PMID: 33357499 Clinical Trial.
[Asthma exacerbations: pharmacological prevention].
Grassin-Delyle S, Girodet PO. Grassin-Delyle S, et al. Among authors: girodet po. Rev Mal Respir. 2012 Feb;29(2):232-44. doi: 10.1016/j.rmr.2011.05.018. Epub 2012 Jan 9. Rev Mal Respir. 2012. PMID: 22405116 Review. French.
95 results